Annual CFF
$50.46 M
+$17.85 M+54.76%
31 December 2023
Summary:
Esperion Therapeutics annual cash flow from financing activities is currently $50.46 million, with the most recent change of +$17.85 million (+54.76%) on 31 December 2023. During the last 3 years, it has fallen by -$151.26 million (-74.99%). ESPR annual CFF is now -81.19% below its all-time high of $268.22 million, reached on 31 December 2021.ESPR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$9.10 M
+$20.93 M+69.71%
30 September 2024
Summary:
Esperion Therapeutics quarterly cash flow from financing activities is currently -$9.10 million, with the most recent change of +$20.93 million (+69.71%) on 30 September 2024. Over the past year, it has dropped by -$4.78 million (-110.92%). ESPR quarterly CFF is now -104.26% below its all-time high of $213.41 million, reached on 31 December 2021.ESPR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$55.96 M
-$4.78 M-7.87%
30 September 2024
Summary:
Esperion Therapeutics TTM cash flow from financing activities is currently $55.96 million, with the most recent change of -$4.78 million (-7.87%) on 30 September 2024. Over the past year, it has increased by +$40.33 million (+258.00%). ESPR TTM CFF is now -80.53% below its all-time high of $287.48 million, reached on 31 March 2015.ESPR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESPR Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +54.8% | -110.9% | +258.0% |
| 3 y3 years | -75.0% | -348.8% | -75.2% |
| 5 y5 years | +371.9% | -1031.9% | -56.8% |
ESPR Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -81.2% | +54.8% | -104.3% | +70.0% | -79.8% | +258.0% |
| 5 y | 5 years | -81.2% | +371.9% | -104.3% | +70.0% | -79.8% | +258.0% |
| alltime | all time | -81.2% | +3336.7% | -104.3% | +70.0% | -80.5% | +3689.4% |
Esperion Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.10 M(-69.7%) | $55.96 M(-7.9%) |
| June 2024 | - | -$30.02 M(-133.1%) | $60.74 M(-33.7%) |
| Mar 2024 | - | $90.61 M(+1926.5%) | $91.57 M(+81.5%) |
| Dec 2023 | $50.46 M(+54.8%) | $4.47 M(-203.7%) | $50.46 M(+222.8%) |
| Sept 2023 | - | -$4.31 M(-633.0%) | $15.63 M(-76.4%) |
| June 2023 | - | $809.00 K(-98.4%) | $66.23 M(-20.7%) |
| Mar 2023 | - | $49.49 M(-263.0%) | $83.53 M(+156.2%) |
| Dec 2022 | $32.61 M(-87.8%) | -$30.36 M(-165.6%) | $32.61 M(-88.2%) |
| Sept 2022 | - | $46.29 M(+155.6%) | $276.37 M(+18.2%) |
| June 2022 | - | $18.11 M(-1361.0%) | $233.74 M(-11.7%) |
| Mar 2022 | - | -$1.44 M(-100.7%) | $264.74 M(-1.3%) |
| Dec 2021 | $268.22 M(+33.0%) | $213.41 M(+5738.9%) | $268.22 M(+19.1%) |
| Sept 2021 | - | $3.65 M(-92.6%) | $225.25 M(+0.9%) |
| June 2021 | - | $49.11 M(+2301.6%) | $223.19 M(+25.6%) |
| Mar 2021 | - | $2.04 M(-98.8%) | $177.76 M(-11.9%) |
| Dec 2020 | $201.72 M(+48.1%) | $170.44 M(>+9900.0%) | $201.72 M(+426.7%) |
| Sept 2020 | - | $1.60 M(-56.5%) | $38.30 M(+1.6%) |
| June 2020 | - | $3.67 M(-85.9%) | $37.68 M(-76.5%) |
| Mar 2020 | - | $26.01 M(+270.9%) | $160.54 M(+17.9%) |
| Dec 2019 | $136.19 M(+1173.6%) | $7.01 M(+618.6%) | $136.19 M(+5.2%) |
| Sept 2019 | - | $976.00 K(-99.2%) | $129.52 M(+0.9%) |
| June 2019 | - | $126.54 M(+7481.5%) | $128.42 M(+4083.1%) |
| Mar 2019 | - | $1.67 M(+388.0%) | $3.07 M(-71.3%) |
| Dec 2018 | $10.69 M(-93.5%) | $342.00 K(-371.4%) | $10.69 M(+4.1%) |
| Sept 2018 | - | -$126.00 K(-110.6%) | $10.27 M(-94.1%) |
| June 2018 | - | $1.19 M(-87.2%) | $174.46 M(+0.9%) |
| Mar 2018 | - | $9.29 M(<-9900.0%) | $172.90 M(+5.8%) |
| Dec 2017 | $163.46 M | -$81.00 K(-100.0%) | $163.46 M(+0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | $164.06 M(<-9900.0%) | $163.13 M(<-9900.0%) |
| June 2017 | - | -$369.00 K(+146.0%) | -$1.32 M(-1.6%) |
| Mar 2017 | - | -$150.00 K(-63.5%) | -$1.34 M(-13.7%) |
| Dec 2016 | -$1.56 M(-100.8%) | -$411.00 K(+4.3%) | -$1.56 M(+1.8%) |
| Sept 2016 | - | -$394.00 K(+1.0%) | -$1.53 M(+51.4%) |
| June 2016 | - | -$390.00 K(+7.1%) | -$1.01 M(+295.3%) |
| Mar 2016 | - | -$364.00 K(-5.2%) | -$256.00 K(-100.1%) |
| Dec 2015 | $190.52 M(+96.2%) | -$384.00 K(-404.8%) | $190.52 M(-32.6%) |
| Sept 2015 | - | $126.00 K(-65.6%) | $282.80 M(-0.0%) |
| June 2015 | - | $366.00 K(-99.8%) | $282.81 M(-1.6%) |
| Mar 2015 | - | $190.41 M(+107.2%) | $287.48 M(+196.0%) |
| Dec 2014 | $97.12 M(+9.0%) | $91.90 M(>+9900.0%) | $97.12 M(+1823.5%) |
| Sept 2014 | - | $134.00 K(-97.3%) | $5.05 M(-93.6%) |
| June 2014 | - | $5.04 M(+9586.5%) | $78.35 M(-12.2%) |
| Mar 2014 | - | $52.00 K(-129.9%) | $89.19 M(+0.1%) |
| Dec 2013 | $89.14 M(+465.9%) | -$174.00 K(-100.2%) | $89.14 M(-6.2%) |
| Sept 2013 | - | $73.43 M(+362.3%) | $95.03 M(+271.0%) |
| June 2013 | - | $15.88 M(>+9900.0%) | $25.62 M(+162.7%) |
| Mar 2013 | - | $0.00(-100.0%) | $9.75 M(-38.1%) |
| Dec 2012 | $15.75 M(+134.5%) | $5.71 M(+42.2%) | $15.75 M(+56.9%) |
| Sept 2012 | - | $4.02 M(>+9900.0%) | $10.04 M(+66.8%) |
| June 2012 | - | $17.40 K(-99.7%) | $6.02 M(+0.3%) |
| Mar 2012 | - | $6.00 M | $6.00 M |
| Dec 2011 | $6.72 M(+366.1%) | - | - |
| Dec 2002 | $1.44 M(-94.2%) | - | - |
| Dec 2001 | $25.02 M(-70.3%) | - | - |
| Dec 2000 | $84.12 M(+2926.9%) | - | - |
| Dec 1999 | $2.78 M | - | - |
FAQ
- What is Esperion Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Esperion Therapeutics?
- What is Esperion Therapeutics annual CFF year-on-year change?
- What is Esperion Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly CFF year-on-year change?
- What is Esperion Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Esperion Therapeutics?
- What is Esperion Therapeutics TTM CFF year-on-year change?
What is Esperion Therapeutics annual cash flow from financing activities?
The current annual CFF of ESPR is $50.46 M
What is the all time high annual CFF for Esperion Therapeutics?
Esperion Therapeutics all-time high annual cash flow from financing activities is $268.22 M
What is Esperion Therapeutics annual CFF year-on-year change?
Over the past year, ESPR annual cash flow from financing activities has changed by +$17.85 M (+54.76%)
What is Esperion Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ESPR is -$9.10 M
What is the all time high quarterly CFF for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly cash flow from financing activities is $213.41 M
What is Esperion Therapeutics quarterly CFF year-on-year change?
Over the past year, ESPR quarterly cash flow from financing activities has changed by -$4.78 M (-110.92%)
What is Esperion Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ESPR is $55.96 M
What is the all time high TTM CFF for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM cash flow from financing activities is $287.48 M
What is Esperion Therapeutics TTM CFF year-on-year change?
Over the past year, ESPR TTM cash flow from financing activities has changed by +$40.33 M (+258.00%)